Trial watch: HIV integrase inhibitor-based regimen beats market leader


positive results from the Phase III SINGLE trial of their investigational HIV integrase inhibitor, dolutegravir, in treatment-naive adults with HIV-1. The dolutegravir-based regimen demonstrated superiority over the most widely prescribed HIV combination therapy, Atripla (Gilead/BMS). Although there is no cure for HIV infection, progression to symptomatic… (More)
DOI: 10.1038/nrd3836